MCAM and melanoma: However, the therapeutic effectiveness in the TS/A tumor model was still lower than that in the murine melanoma tumor model B16F10 using GET of plasmids silencing either CD105 or CD146 alone; specifically, silencing CD105 in melanoma resulted in pronounced tumor growth delay (8.6 days) and tumor-free mice (44%), from which the majority were also resistant to secondary challenge (75%) [30].